New pill combo aims to fight Hard-to-Treat breast cancer
NCT ID NCT07557004
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new oral drug, SH3765, combined with the injectable hormone therapy fulvestrant in 30 women with advanced HR+/HER2- breast cancer that has worsened after prior treatment. The main goals are to check safety, find the best dose, and see if the combination shrinks tumors. Results will guide whether larger studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SH3765 tablets and fulvestrant injection
What this could lead to
If it works, this could point toward a new combination treatment for advanced HR+/HER2- breast cancer that has stopped responding to prior hormone therapy.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so it is primarily testing safety and dosing. It is too small to prove effectiveness, and the drug may not work or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital Of USTC Anhui Provincial Hospital
Hefei, Anhui, China